RECRUITING

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

Official Title

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Quick Facts

Study Start:2024-06-26
Study Completion:2029-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06207032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. ≥18 years of age
  2. 2. Willing to participate in the research
  3. 3. Able to provide informed consent
  4. 4. Must be diagnosed with cancer
  1. 1. Not willing or able to have additional blood samples collected

Contacts and Locations

Study Contact

Lauren Lopez
CONTACT
8007394137
aries@tempus.com

Principal Investigator

Michelle Ting-Lin, MD
STUDY_DIRECTOR
Tempus AI, Inc.

Study Locations (Sites)

Alabama Oncology
Birmingham, Alabama, 35233
United States
Eastern CT and Hematology and Oncology Associates
Norwich, Connecticut, 06360
United States
Southern Illinois Healthcare
Carterville, Illinois, 62918
United States
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521
United States
Cancer Care Specialists of Illinois
O'Fallon, Illinois, 62269
United States
Illinois Cancer Care
Peoria, Illinois, 61615
United States
Northwest Oncology and Hematology
Rolling Meadows, Illinois, 60008
United States
Fort Wayne
Fort Wayne, Indiana, 46804
United States
St. Claire Healthcare
Morehead, Kentucky, 40351
United States
Lake Regional Health
Osage Beach, Missouri, 65065
United States
Oncology Hematology Associates
Springfield, Missouri, 65807
United States
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
United States
New Jersey Cancer Center
Belleville, New Jersey, 07109
United States
Regional Cancer Care Associates
Belleville, New Jersey, 07109
United States
Hematology Oncology Associates of Central NY
East Syracuse, New York, 13057
United States
Cayuga Medical Center
Ithaca, New York, 14850
United States
Taylor Cancer Research Center
Maumee, Ohio, 43537
United States
Cancer Care Associates of York
York, Pennsylvania, 17403
United States

Collaborators and Investigators

Sponsor: Tempus AI

  • Michelle Ting-Lin, MD, STUDY_DIRECTOR, Tempus AI, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-26
Study Completion Date2029-06-01

Study Record Updates

Study Start Date2024-06-26
Study Completion Date2029-06-01

Terms related to this study

Keywords Provided by Researchers

  • ctDNA
  • Next-Generation Sequencing
  • Oncology

Additional Relevant MeSH Terms

  • Cancer